The SMC has indefinitely suspended meetings of its SMC Committee and New Drugs Committee until further notice as a result of the COVID-19 pandemic.
This comes as an update to their initially announced timelines, which proposed meetings would restart at the end of May. Meanwhile, other HTA bodies, such as NICE (which shifted its HTA focus and Methods Review timelines in March) is now beginning to re-start its non-COVID-19 related therapy reviews.
The Scottish Medicines Consortium (SMC) decision has been made in order to allow committee members to work on projects more closely aligned with COVID-19 strategies. It has been reported that some committee members will review new urgent medicines submissions regarding COVID-19 as required, however, no new or re-submissions will be accepted at present.
In a statement issued by SMC, it stated that it is “exploring how best to progress prompt decision-making for submissions…” once the meetings resume.